Identify M. tuberculosis complex species and susceptibility.
Identification/Susceptibility. Methods may include biochemical, mass spectrometry, nucleic acid probe, polymerase chain reaction, or sequencing.
Sun-Sat
Varies (depends on organism growth)
Actively growing organism, in pure culture.
Transport sealed container with pure culture on solid or in liquid media. Place each specimen in an individually sealed bag.
Room temperature. If culture is suspected of being a microorganism identified on the IATA list as an infectious substance affecting humans, submit specimen according to Infectious Substance, Category A, shipping guidelines.
Mixed cultures or non-viable organisms. Organisms submitted on agar plate.
Indicate source of organism and any other pertinent information such as growth rate of the organism or DNA probe results.
Ambient: 2 weeks; Refrigerated: 2 weeks; Frozen: 2 weeks
Complete identification and susceptibility of clinically significant isolates of M. tuberculosis complex, M. kansasii, M. avium-intracellulare complex, M. fortuitum complex, M. abscessus complex, M. chelonae, M. immunogenum and any isolate from a significant source.
For identification by DNA sequencing and MALDI-TOF:
See Compliance Statement B: www.aruplab.com/CS
Depends on Specimen/Source/Method
If a significant organism listed above is identified, then the appropriate susceptibility panel will be added. Additional charges apply. For other organisms, contact ARUP if susceptibility testing is clinically indicated.
A processing fee will be billed for all organisms submitted that are not in pure culture as requested in the specimen requirements. Identification of AFB isolates is billed by individual tests performed.
CPT codes for identification and susceptibility vary based on method.
Component Test Code* | Component Chart Name | LOINC |
---|---|---|
0060997 | AFB Identification/Susceptibility | 29579-0 |
- ID by sequencing
- M. tuberculosis identification
- MA AFB
- Mycobacteria identification
- Mycobacterium tuberculosis identification
- Primary Anti-tuberculosis agents
- Primary Panel